The technology and applications of single-cell analysis have advanced dramatically in the last five years- 2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference

The technology and applications of single-cell analysis have advanced dramatically in the last five years- 2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference

2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference to be held on 9th – 10th November 2021 will host industry giants like San Diego Nanotechnology Infrastructure, CHDI Foundation, Brigham Young University, AbSci, Stowers Institute for Medical Research, University of Florence, Pfizer, l’Université et CHU de Montpellier and many more. The single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period. The growth in this market is driven by technological advancements in single-cell analysis products,…

Read More

Multiple factors & challenges preventing cell and gene therapies to be widely used- 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference

Multiple factors & challenges preventing cell and gene therapies to be widely used- 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference

3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference to be held on 28th – 29th October 2021 will host industry giants like Advanced Cell & Gene Therapy LLC, Cell & Gene Therapy Consulting LLC, panCella, Sigilon Inc, Biotechnology Biopharmaceuticals and many more. The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of…

Read More

Real World Evidence is key for pharma organizations in drug development- 5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference

Real World Evidence is key for pharma organizations in drug development- 5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference

5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone – EST) to be held on 19th – 22nd October 2021 will host industry giants like Sarepta Therapeutics, Idorsia Pharmaceuticals, Food and Drug Administration (FDA), AveXis, Rafael Pharmaceuticals, PicnicHealth, Dedalus Group, RTI Health Solutions, Bluebird Bio, Seagen, Takeda, Takeda Pharmaceuticals, Novartis, OM1 and many more. The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%. The growth of this…

Read More

Discovering the future of infection prevention and control – 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference 2021

Discovering the future of infection prevention and control – 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference 2021

July 12th, 2021- Following up the legacy of 5 very successful annuals in UK & Europe geographies, we are proud to to announce the 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference, Middle East, scheduled for 5th-6th October, 2021. This edition will focus on key topics like the utilization of reprocessed equipment to disinfect or sterilize medical devices, decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines. How Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilising medical devices. These topics…

Read More

Delve into the new era of genome sequencing- MarketsandMarkets Advanced Genetic Sequencing Virtual Conference

Delve into the new era of genome sequencing- MarketsandMarkets Advanced Genetic Sequencing Virtual Conference

July 12th, 2021- Genome sequencing is providing physicians with more data about the causes of cancer and changing the way some forms of the disease are treated. Continued advancements in sequencing technologies have fuelled the development of new sequencing applications. MarketsandMarkets is proud to announce the first edition of Advanced Genetic Sequencing Virtual Conference scheduled to be held on 23rd & 24th of September 2021. A 2-day content-rich program combining stellar expertise from world-renowned keynote and featured speakers in the areas of Genetics & Genomics an expanding field of biology…

Read More

Embracing next-generation technologies for new-age digitization- MarketsandMarkets Plant Digitization Virtual Conference 2021

Embracing next-generation technologies for new-age digitization- MarketsandMarkets Plant Digitization Virtual Conference 2021

July 08th, 2021- Digitization – through SMART TECHNOLOGIES and CONNECTED DEVICES- is increasing PRODUCTIVITY, EFFICENCY AND ACCURACY in manufacturing and process-based enterprises. Industry experts believe, in future virtually all plant operations will be converted into a digital format.  We, along with HIMA as our co-sponsor, are proud to present you the APAC edition of MarketsandMarkets Plant Digitization Virtual Conference which is scheduled to take place on 19th – 20th August 2021. The 2-day conference will extend the opportunity to explore the technological advances and innovations in the field of Plant…

Read More

Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021

Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021

July, 08th 2021 – 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021 to be held on the 26th-29th October 2021 will host top tier institutes pharmaceutical, bio-pharmaceutical and biotechnology companies like Scancell, Regeneron Pharmaceuticals, Cancer Vaccines Ltd, Boston Immune Technologies & Therapeutics & more to deliver the key challenges and future directions in IO research and to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors    The conference aims to bring together 25+ industry thought leaders & 200+ attendees from pharmaceutical and…

Read More

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”-  A brief discussion with Juan Perez Villar, CEO, LeadArtis.

Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…

Read More

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…

Read More

Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. William Williams of  Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…

Read More